Neurology

The agency has also approved the baclofen oral suspension for Azurity Pharmaceuticals to treat individuals with other spinal cord diseases or injuries.

Many people who experience a grand mal seizure never have another one and don't need treatment.

Gliomas begin in the glial cells that surround nerve cells and help them function.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

Agency green light could help get medication off ASHP drug shortage list by reducing supply issues.

Study results suggest that infection with Epstein-Barr virus may be the leading cause of multiple sclerosis.

Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Study data showed that increased levels of infection, inflammation, and metabolic alterations frequently observed in people with depression and psychosis may be a cause rather than a consequence of these disorders.

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

Generalized anxiety disorder has symptoms that are similar to panic disorder, obsessive-compulsive disorder, and other types of anxiety.

The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

This is an update to the 2011 AAN guideline on the treatment of painful diabetic neuropathy, according to a press release.

When using a therapy to clear the senescent cells, disease progression and cell death were stopped, according to the study.

Nurtec is the first oral calcitonin gene-related peptide antagonist approved for both acute and preventative treatment of migraine.

Inhibiting the activity of group 3 innate lymphoid cells could serve as a new therapeutic approach for neurologic conditions.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the problems with approaching public health issues, such as mental health and substance use disorders, with an industrialized approach to problem solving.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which environments each psychedelic medicine is likely to be administered.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

A panel of experts discuss the future of psychedelic medicine and the role of the pharmacy in that future.

Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.

Saol Therapeutics also announces the acquisition of 4 plasma-derived hyperimmune products by Kamada, which will be invested to help launch Lyvispah and other pipeline developments.

About 74% of individuals who remained on cenobamate had early-onset responder rates and high rates of sustained seizure reduction for as long as 43 months, study results show.

Febrile seizures occur in young, healthy children with normal development.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Alzheimer disease.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

Ron Aung-Din, MD, the clinical medical advisor of Pyscheceutical, and Chad Harman, the CEO of Pyscheceutical, discuss a novel approach for administering psychedelics for the treatment of brain disorders that does not induce hallucinogenic effects.

Ocrelizumab is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease, in adults.